SKB264 Clinical Trials
8 recruitingDrug
Phase 35Phase 23
Showing 1–8 of 8 trials
Recruiting
Phase 2
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
Non-small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.110 enrolled2 locationsNCT05351788
Recruiting
Phase 2
Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC
Ovarian Epithelial Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.20 enrolled1 locationNCT07341100
Recruiting
Phase 3
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Triple-Negative Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.524 enrolled1 locationNCT06279364
Recruiting
Phase 3
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
Metastatic Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.376 enrolled1 locationNCT06081959
Recruiting
Phase 3
A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
Metastatic Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.430 enrolled2 locationsNCT07071337
Recruiting
Phase 3
A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.420 enrolled2 locationsNCT06670196
Recruiting
Phase 3
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.432 enrolled1 locationNCT06711900
Recruiting
Phase 2
Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer
Breast Cancer
Shanghai Jiao Tong University School of Medicine40 enrolled1 locationNCT07371208